Azathioprine, Used to Treat IBD, Linked to Skin Cancer, Researchers Warn

Azathioprine, Used to Treat IBD, Linked to Skin Cancer, Researchers Warn
Azathioprine, used to treat inflammatory bowel disease, arthritis, and other conditions, has been linked to the development of skin cancer in a group of patients. In the study "The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature," researchers recommend that sun protection, skin surveillance, and early identification and removal of lesions be part of the management of patients on azathioprine. Cutaneous squamous cell carcinoma (cSCC) is a common form of skin cancer, with about 1 million new cases reported in the U.S. every year. Despite its high incidence, scientists are still in the dark regarding the molecular mechanisms behind the development and progression of cSCC. Advances in genetic analyses have led to the identification of mutations (or combinations of mutation types) referred to as "mutational signatures" that characterize specific types of cancers and are listed in the catalogue of somatic mutations in cancer (COSMIC). The study, published in the journal Nature Communications, applied a genetic analysis method known as whole-exome sequencing (WES) in order to establish a mutational signature of cSCC. In doing so, the researchers identified an association between this signature and use of azathioprine, which is used to treat inflammatory bowel disease (IBD), arthritis, vasculitis, and is used as an immunosuppressant following organ transplants. The researchers used WES to analyze the genetic prof
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *